Matchpoint Closes 150 Million Dollar Series B
Matchpoint Therapeutics closed a $150 million Series B to advance precision covalent small molecules for autoimmune and inflammatory disease. The round is material new capital and should carry lead program MPT-062 into clinical proof…
